Ensign Peak Advisors Inc Has $142.27 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Ensign Peak Advisors Inc cut its stake in Boston Scientific Co. (NYSE:BSX) by 17.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,847,392 shares of the medical equipment provider’s stock after selling 380,423 shares during the period. Ensign Peak Advisors Inc owned approximately 0.13% of Boston Scientific worth $142,268,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Summit Trail Advisors LLC raised its position in Boston Scientific by 15.0% during the second quarter. Summit Trail Advisors LLC now owns 10,767 shares of the medical equipment provider’s stock valued at $829,000 after purchasing an additional 1,403 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Boston Scientific by 71.6% in the second quarter. Thrivent Financial for Lutherans now owns 333,963 shares of the medical equipment provider’s stock worth $25,718,000 after acquiring an additional 139,392 shares during the last quarter. Sei Investments Co. grew its holdings in shares of Boston Scientific by 3.0% during the 2nd quarter. Sei Investments Co. now owns 4,710,266 shares of the medical equipment provider’s stock valued at $362,739,000 after purchasing an additional 137,397 shares during the last quarter. AE Wealth Management LLC increased its position in Boston Scientific by 18.9% during the 2nd quarter. AE Wealth Management LLC now owns 16,261 shares of the medical equipment provider’s stock worth $1,252,000 after purchasing an additional 2,582 shares in the last quarter. Finally, Simplify Asset Management Inc. lifted its stake in Boston Scientific by 27.5% in the 2nd quarter. Simplify Asset Management Inc. now owns 79,639 shares of the medical equipment provider’s stock valued at $6,133,000 after purchasing an additional 17,181 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the transaction, the executive vice president now owns 40,188 shares in the company, valued at $2,978,734.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 20,949 shares of company stock worth $1,627,877. Company insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of research reports. StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, September 13th. Evercore ISI lifted their target price on shares of Boston Scientific from $78.00 to $81.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 2nd. Canaccord Genuity Group lifted their price objective on Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Royal Bank of Canada restated an “outperform” rating and set a $85.00 target price on shares of Boston Scientific in a research report on Thursday, July 25th. Finally, The Goldman Sachs Group initiated coverage on shares of Boston Scientific in a report on Thursday, May 30th. They issued a “buy” rating and a $90.00 price target for the company. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $85.38.

Boston Scientific Stock Up 0.3 %

Shares of NYSE:BSX opened at $83.92 on Friday. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $84.89. The business has a fifty day moving average price of $78.72 and a two-hundred day moving average price of $74.63. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14. The company has a market capitalization of $123.12 billion, a PE ratio of 70.52, a price-to-earnings-growth ratio of 2.75 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The firm had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. During the same period in the prior year, the firm earned $0.53 EPS. The company’s revenue was up 14.5% compared to the same quarter last year. Analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.